Companies
QIAGEN
Molecular diagnostics leader — QIAstat-Dx, QIAamp extraction kits, and QIAsymphony automation; nucleic acid extraction reagents used in 90% of global CRISPR diagnostics workflows.
- Country
- Netherlands
- Revenue
- $2.0B
- Employees
- ~6,100 emp
ISO 13485
GMP EU
CE-IVD
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| analytics-pat | ✓ | ✓ | — | ✓ |
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
| diagnostics-medtech | ✓ | ✓ | — | ✓ |
| monitoring-conservation | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpausda-aphismoa-chinaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headcount | approximately 5,700 people (2025-12-31) | corporate.qiagen.com · marketscreener.com · sec.gov · stocktitan.net |
| Revenue | $2.09 billion (2025-12-31) | corporate.qiagen.com · sec.gov · stocktitan.net |
| Production site | United States, Germany, Spain, and China | s28.q4cdn.com · marketscreener.com |
| Certification | ISO 9001:2015, ISO 13485:2016, and MDSAP | s28.q4cdn.com · marketscreener.com |
| Regulatory approval | FDA Quality System Regulations (cGMP) compliant | s28.q4cdn.com · marketscreener.com |
| Funding | Internally generated funds and debt offerings | s28.q4cdn.com · marketscreener.com · sec.gov |
| Capacity | Capacity reached over 20 million patient tests per month by end of 2020 for RNA extraction kits medium confidence | dutchnews.nl |
Independent sources: dutchnews.nl · marketscreener.com · s28.q4cdn.com · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated nucleic acid extraction | analytics-pat | Low | → |
| Biological AI & bioinformation services | bioinformatics-omics | Medium | → |
| Capillary electrophoresis for biopharma | analytics-pat | Low | → |
| CRISPR diagnostics | diagnostics-medtech | Medium | → |
| Personalized diagnostics | diagnostics-medtech | Low | → |
| Sovereign genome databases (plants, animals, microbes) | monitoring-conservation | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.